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Abstract
Introduction: Aripiprazole is a novel atypical neuroleptic used in the treatment of psychosis. A few
recent studies have demonstrated an association between the use of aripiprazole and an exacerbation
of Parkinsonism, although this relationship is poorly defined. To our knowledge, this is the first case
series describing an onset of Parkinsonism in patients without prior history of Parkinson’s disease
following aripiprazole treatment.
Case presentation: We describe two patients, ages 69 and 58, who developed cardinal features of
Parkinson’s disease shortly after receiving aripiprazole. Both patients were male veterans with a
history of bipolar disorder treated with aripiprazole. They initially presented with asymmetric arm
tremor, and subsequently developed rigidity, bradykinesia, and postural instability. On examination,
they were found to be at a Hoehn and Yahr stage of 2.5 for their Parkinsonism.
Conclusions: While aripiprazole has been associated with infrequent extrapyramidal side effects,
these cases raise concerns that its chronic exposure may lead to D2 receptor hypersensitivity and/or
dysfunction and subsequent development of a syndrome mimicking idiopathic Parkinson’s disease.
With the available atypical neuroleptics becoming widely used in treating psychotic symptoms
associated with a broad range of disorders, we advise closer monitoring due to their potential for
inducing Parkinsonism.
Introduction
Aripiprazole is one of the recently introduced atypical
antipsychotics (AAs) used in the treatment of psychosis
related to schizophrenia [1], depression [2], bipolar
disorder [3], and Parkinson’s disease (PD) [4]. Well-
documented side effects associated with the use of
aripiprazole include insomnia, anxiety, headaches, nau-
sea, vomiting, and somnolence [5]. As with other AAs,
aripiprazole has been associated with fewer extrapyrami-
dal side effects (EPS) that are thought to arise from a
greater than 80% D2 receptor occupancy rate in the striatal
area of the basal ganglia [6]. The differential EPS profile of
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action as a partial agonist at dopamine D2 and serotonin
5-HT1a receptors. Additionally, the drug functions as an
antagonist at serotonin 5-HT2a receptors. Such mechan-
ism of action is believed to stimulate dopamine release via
a feedback loop in the basal ganglia [6]. Given its unique
pharmacologic profile, aripiprazole may have a greater
potential for worsening Parkinsonism than other AAs.
Many studies have extensively described the EPS profiles
of earlier atypical neuroleptics, namely clozapine, quetia-
pine, olanzapine, ziprasidone and risperidone [6]. The
relationship between aripiprazole treatment and Parkin-
sonism, however, remains poorly defined. Findings from
recent studies have been inconsistent, reporting a wide
range of motor effects following treatment with the agent
[7]. Furthermore, the majority of these studies involve
patients already diagnosed with PD. Given our limited
experience with aripiprazole, its association with features
of PD has yet to be delineated. In this report, we describe
two unique cases of the association between aripiprazole
treatment and the onset of Parkinsonism in patients
without a prior history of PD or tremor.
Case presentation
Case report 1
Patient 1 is a 69-year-old, right-handed Caucasian male
with a history of bipolar disorder type one. During the two
years prior to his initial presentation in our movement
disorders clinic, the patient had been taking aripiprazole
daily for treatment of psychosis. Eighteen months follow-
ing initial treatment, he developed right arm resting
tremor and was subsequently given a higher dose of
aripiprazole (10 mg) by his psychiatrist. Initially, his
tremor occurred only at rest; later, he developed both
resting and postural tremor, affecting his ability to hold
things. His writing and other fine motor movements,
however, were unaffected. Although no change in speech,
cognition, or behavior had been noted, the patient
reported that, in the months preceding his initial
neurological evaluation, he had been unsteady on his
feet, with an increased tendency to stumble. In spite of
these symptoms, he remained independent and fully
engaged in his activities of daily living.
On clinical examination, he was found to have mild
hypomimia (see additional file: Movie1) and hypopho-
nia, and was also mildly bradyphrenic. He had resting and
postural tremors, as well as mild rigidity of his arms, with
symptoms being more prominent on the right (see
additional file: Movie1). He was also dysdiadochokinetic
while seated and had a reduced arm swing when walking
(see additional file: Movie1). He scored 2.5 on the Hoehn
and Yahr staging and 29/30 on the mini-mental status
exam. The rest of his neurological examination was
unremarkable, except for a reduced sensation to light
touch and vibration in his distal lower extremities. His
brain MRI scans were normal, with some age-appropriate
volume loss. Due to fluctuations in his psychotic
symptoms, aripiprazole could not be stopped or
decreased. Sinemet was subsequently started, with notice-
able improvement in tremors and gait. We observed
further improvement in his Parkinsonism after the
addition of trihexyphenidyl.
Case report 2
Patient 2 is a 58-year-old, right-handed Caucasian male
with a four-year history of bipolar disorder and post-
traumatic stress disorder, for which he was placed on
aripiprazole and depakote, respectively. While on both
medications, he experienced a gradual onset of arm tremor
on the right side, followed by the left side a few months
later. Since this initial onset, his tremor progressed to a
constant condition, occurring both at rest and while eating
and drinking. Depakote was stopped a few months prior
to his neurological evaluation, with no noticeable
improvement in his tremor. In contrast, his tremors over
the following months became more pronounced, affecting
his drinking, eating, and writing. At this point, the patient
also complained about gait unsteadiness leading to
frequent falls.
On examination, the patient was hypomimic and mildly
bradyphrenic. He had positive Myerson’s sign, as well as
rest and action/postural tremor. He also presented with
rigidity of his arms, which was worse on the left, and an
unstable, leftward leaning gait. His arm swing was reduced
bilaterally, although worse on the left, and his arm tremors
became more pronounced during ambulation. In addi-
tion, the patient was retropulsive. His Hoehn and Yahr
staging was 2.5. He also demonstrated a decreased
sensation to pinprick and vibration in the ankles. Overall,
his symptoms were more prominent on the left side than
on the right. As in the previous case, aripiprazole could not
be stopped or decreased, but his tremors improved after
two weeks on Sinemet.
Discussion
The introduction of second-generation antipsychotics
(SGAs) in the mid 1990s allowed clinicians to treat
patients suffering from psychosis with a significantly
reduced risk of developing EPS, compared to their first-
generation counterparts, such as haloperidol [8]. The two
cases presented in this report suggest that aripiprazole
might be associated with the appearance of Parkinsonism
when patients are on the drug for a certain length of time.
While the optimal duration of exposure is currently not
known for the induction of Parkinsonism [9], long-term
use of these drugs should be monitored closely to avoid
such adverse effects.
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vulnerable AAs in developing EPS based on its partial D2
agonistic and serotonin 5-HT1a agonistic property [4], the
cases presented here raise concerns that its chronic
exposure may lead to D2 receptor hypersensitivity and/
or dysfunction and subsequent development of a parkin-
sonian syndrome mimicking idiopathic PD [10]. Thus,
given its propensity to not only worsen, but also induce
Parkinsonism, this medication should be administered
with caution.
While both patients developed cardinal features of PD
following treatment with aripiprazole, we are not certain
whether these findings represent a drug effect or simply an
unmasking of PD. Despite uncertainty regarding the actual
mechanism, these reports further contribute to the
literature demonstrating an association between exposure
to aripiprazole and the onset of Parkinsonism. Our
preliminary findings can serve as a starting point for
future work that investigates the potential mechanism of
action of aripiprazole leading to these unwanted effects.
With the increasing utilization of AAs in treating psychoses
and psychotic symptoms in PD and other neurodegenera-
tive disorders, we recommend close monitoring of these
agents for safeguarding. A more comprehensive under-
standing of drug-receptor interactions of AAs may aid in a
more efficacious utilization of these medications while
minimizing the risk of developing and/or worsening
Parkinsonism.
Conclusion
We report two cases describing the association between the
use of aripiprazole and the onset of Parkinsonism. This
represents the first series of such an association in cases of
psychosis without PD. Our study emphasizes the need for
careful surveillance for the development of Parkinsonian
features in patients treated with aripiprazole. The side
effect profile of this medication has yet to be better
characterized. Given the increasing clinical application of
aripiprazole and other SGAs, we believe that further
investigation on this relationship is warranted.
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Additional File (Movie)
File name: movie1 (http://jmedicalcasereports.com/jmedi-
calcasereports/article/downloadSuppFile/6448/14502)
File format: MOV (QuickTime)
Title of data: Neurological examination – Patient 1
Description of data: In this video clip, we demonstrate the
neurological examination of Patient 1 during his second
visit to the movement disorders clinic. He displays the
following Parkinsonian features, in chronological order:
hypomimia, resting tremor, postural tremor, irregular and
reduced finger-tapping movements (R>L), and reduced
arm swing.
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